Results of the 2nd Scientific Workshop of the ECCO (III): Basic mechanisms of intestinal healing

Journal of Crohn's and Colitis

Volumn 6, Issue 3, 2012, Pages 373-385

  Rieder, Florian ^a   Karrasch, Thomas ^b   Ben Horin, Shomron ^c   Schirbel, Anja ^d   Ehehalt, Robert ^e   Wehkamp, Jan ^f   de Haar, Colin ^g   Velin, Dominique ^h   Latella, Giovanni ⁱ   Scaldaferri, Franco ^j   Rogler, Gerhard ^k   Higgins, Peter ^l   Sans, Miquel ^m  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c TEL AVIV UNIVERSITY   (Israel)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ UNIVERSITY OF L'AQUILA   (Italy)

^j FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^k UNIVERSITY OF ZURICH   (Switzerland)

^l UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^m HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

Crohn's disease; Fibrosis; Fistula; Genetic variants; Inflammatory bowel diseases; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BUDESONIDE; BUTYRIC ACID; CIPROFLOXACIN; CYCLOSPORIN A; DEXAMETHASONE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GRANZYME B; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 23; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LEPTIN; MATRIX METALLOPROTEINASE 14; MESALAZINE; METRONIDAZOLE; PREDNISOLONE; PROBIOTIC AGENT; RIFAXIMIN; SALAZOSULFAPYRIDINE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

CELL ACTIVATION; CROHN DISEASE; DISEASE COURSE; DRUG MECHANISM; ENZYME ACTIVITY; ESCHERICHIA COLI; EUROPEAN CROHNS AND COLITIS ORGANIZATION; EXTRACELLULAR MATRIX; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEALTH CARE ORGANIZATION; HUMAN; INTESTINE HEALING; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; WORKSHOP; WOUND HEALING;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BUTYRIC ACID; COLITIS, ULCERATIVE; CROHN DISEASE; CYCLOSPORINE; DEFENSINS; EXTRACELLULAR MATRIX; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; LEPTIN; MATRIX METALLOPROTEINASES; MESALAMINE; PANETH CELLS; PROBIOTICS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; SULFASALAZINE; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 84858079585     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.11.009     Document Type: Review

References (135)

1. Yan F., Cao H., Cover T.L., Whitehead R., Washington M.K., Polk D.B. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007 Feb, 132(2):562-575.
2. Nenci A., Becker C., Wullaert A., Gareus R., van Loo G., Danese S., et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007 Mar 29, 446(7135):557-561.
3. Frey M.R., Golovin A., Polk D.B. Epidermal growth factor-stimulated intestinal epithelial cell migration requires Src family kinase-dependent p38 MAPK signaling. J Biol Chem 2004 Oct 22, 279(43):44513-44521.
4. Yamaoka T., Yan F., Cao H., Hobbs S.S., Dise R.S., Tong W., et al. Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis. Proc Natl Acad Sci U S A 2008 Aug 19, 105(33):11772-11777.
5. Akazawa A., Sakaida I., Higaki S., Kubo Y., Uchida K., Okita K. Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase. J Gastroenterol 2002, 37(5):345-353.
6. McKenzie S.J., Baker M.S., Buffinton G.D., Doe W.F. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 1996 Jul 1, 98(1):136-141.
7. Krieglstein C.F., Cerwinka W.H., Laroux F.S., Salter J.W., Russell J.M., Schuermann G., et al. Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide. J Exp Med 2001 Nov 5, 194(9):1207-1218.
8. Zingarelli B., Szabo C., Salzman A.L. Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase. Gut 1999 Aug, 45(2):199-209.
9. McCafferty D.M., Miampamba M., Sihota E., Sharkey K.A., Kubes P. Role of inducible nitric oxide synthase in trinitrobenzene sulphonic acid induced colitis in mice. Gut 1999 Dec, 45(6):864-873.
10. Kolios G., Rooney N., Murphy C.T., Robertson D.A., Westwick J. Expression of inducible nitric oxide synthase activity in human colon epithelial cells: modulation by T lymphocyte derived cytokines. Gut 1998 Jul, 43(1):56-63.
11. Kruidenier L., Kuiper I., van Duijn W., Marklund S.L., van Hogezand R.A., Lamers C.B., et al. Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease. J Pathol 2003 Sep, 201(1):7-16.
12. Carroll I.M., Andrus J.M., Bruno-Barcena J.M., Klaenhammer T.R., Hassan H.M., Threadgill D.S. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am J Physiol 2007 Oct, 293(4):G729-G738.
13. Han W., Mercenier A., Ait-Belgnaoui A., Pavan S., Lamine F., van S., et al. Improvement of an experimental colitis in rats by lactic acid bacteria producing superoxide dismutase. Inflamm Bowel Dis 2006 Nov, 12(11):1044-1052.
14. von Lampe B., Barthel B., Coupland S.E., Riecken E.O., Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000 Jul, 47(1):63-73.
15. Meijer M.J., Mieremet-Ooms M.A., van der Zon A.M., van Duijn W., van Hogezand R.A., Sier C.F., et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis 2007 Aug, 39(8):733-739.
16. Wang Y.D., Wang W. Protective effect of ilomastat on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats. World J Gastroenterol 2008 Oct 7, 14(37):5683-5688.
17. Koon H.W., Zhao D., Na X., Moyer M.P., Pothoulakis C. Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J Biol Chem 2004 Oct 29, 279(44):45519-45527.
18. Sitaraman S., Liu X., Charrier L., Gu L.H., Ziegler T.R., Gewirtz A., et al. Colonic leptin: source of a novel proinflammatory cytokine involved in IBD. FASEB J 2004 Apr, 18(6):696-698.
19. Chen L.W., Egan L., Li Z.W., Greten F.R., Kagnoff M.F., Karin M. The two faces of IKK and NFκB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003 May, 9(5):575-581.
20. Pagnini C., Saeed R., Bamias G., Arseneau K.O., Pizarro T.T., Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci U S A 2010 Jan 5, 107(1):454-459.
21. Karhausen J., Furuta G.T., Tomaszewski J.E., Johnson R.S., Colgan S.P., Haase V.H. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 2004 Oct, 114(8):1098-1106.
22. Robinson A., Keely S., Karhausen J., Gerich M.E., Furuta G.T., Colgan S.P. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 2008 Jan, 134(1):145-155.
23. Shah Y.M., Ito S., Morimura K., Chen C., Yim S.H., Haase V.H., et al. Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology 2008 Jun, 134(7):2036-2048. 48 e1-3.
24. Leon A.J., Gomez E., Garrote J.A., Bernardo D., Barrera A., Marcos J.L., et al. High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD. Mediators Inflamm 2009, 2009:580450.
25. Fischbeck A., Leucht K., Frey-Wagner I., Bentz S., Pesch T., Kellermeier S., et al. Sphingomyelin induces cathepsin D-mediated apoptosis in intestinal epithelial cells and increases inflammation in DSS colitis. Gut 2011 Jan, 60(1):55-65.
26. Menzel K., Hausmann M., Obermeier F., Schreiter K., Dunger N., Bataille F., et al. Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo. Clin Exp Immunol 2006 Oct, 146(1):169-180.
27. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006 Jul, 3(7):390-407.
28. Ehehalt R., Braun A., Karner M., Fullekrug J., Stremmel W. Phosphatidylcholine as a constituent in the colonic mucosal barrier - physiological and clinical relevance. Biochim Biophys Acta 2010 Sep, 1801(9):983-993.
29. Karrasch T., Jobin C. Wound healing responses at the gastrointestinal epithelium: a close look at novel regulatory factors and investigative approaches. Z Gastroenterol 2009 Dec, 47(12):1221-1229.
30. Turner J.R. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009 Nov, 9(11):799-809.
31. Larsson J.M., Karlsson H., Sjovall H., Hansson G.C. A complex, but uniform O-glycosylation of the human MUC2 mucin from colonic biopsies analyzed by nanoLC/MSn. Glycobiology 2009 Jul, 19(7):756-766.
32. van der Sluis M., Bouma J., Vincent A., Velcich A., Carraway K.L., Buller H.A., et al. Combined defects in epithelial and immunoregulatory factors exacerbate the pathogenesis of inflammation: mucin 2-interleukin 10-deficient mice. Lab Invest 2008 Jun, 88(6):634-642.
33. Kaser A., Lee A.H., Franke A., Glickman J.N., Zeissig S., Tilg H., et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008 Sep 5, 134(5):743-756.
34. Braun A., Treede I., Gotthardt D., Tietje A., Zahn A., Ruhwald R., et al. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis 2009 Nov, 15(11):1705-1720.
35. Johansson M.E., Phillipson M., Petersson J., Velcich A., Holm L., Hansson G.C. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 2008 Sep 30, 105(39):15064-15069.
36. Swidsinski A., Loening-Baucke V., Bengmark S., Lochs H., Dorffel Y. Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. Inflamm Bowel Dis 2007 Jan, 13(1):51-56.
37. Kiesslich R., Goetz M., Angus E.M., Hu Q., Guan Y., Potten C., et al. Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy. Gastroenterology 2007 Dec, 133(6):1769-1778.
38. Watson A.J., Chu S., Sieck L., Gerasimenko O., Bullen T., Campbell F., et al. Epithelial barrier function in vivo is sustained despite gaps in epithelial layers. Gastroenterology 2005 Sep, 129(3):902-912.
39. Stremmel W., Hanemann A., Braun A., Stoffels S., Karner M., Fazeli S., et al. Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis - a review of three clinical trials. Expert Opin Investig Drugs 2010 Dec, 19(12):1623-1630.
40. Vongsa R.A., Zimmerman N.P., Dwinell M.B. CCR6 regulation of the actin cytoskeleton orchestrates human beta defensin-2- and CCL20-mediated restitution of colonic epithelial cells. J Biol Chem 2009 Apr 10, 284(15):10034-10045.
41. Otte J.M., Werner I., Brand S., Chromik A.M., Schmitz F., Kleine M., et al. Human beta defensin 2 promotes intestinal wound healing in vitro. J Cell Biochem 2008 Aug 15, 104(6):2286-2297.
42. Schroeder B.O., Wu Z., Nuding S., Groscurth S., Marcinowski M., Beisner J., et al. Reduction of disulphide bonds unmasks potent antimicrobial activity of human beta-defensin 1. Nature 2011 Jan 20, 469(7330):419-423.
43. Peyrin-Biroulet L., Beisner J., Wang G., Nuding S., Oommen S.T., Kelly D., et al. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A 2010 May 11, 107(19):8772-8777.
44. Wehkamp J., Koslowski M., Wang G., Stange E.F. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease. Mucosal Immunol 2008 Nov, 1(Suppl 1):S67-S74.
45. Wehkamp J., Salzman N.H., Porter E., Nuding S., Weichenthal M., Petras R.E., et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005 Dec 13, 102(50):18129-18134.
46. Dignass A.U. Mechanisms and modulation of intestinal epithelial repair. Inflamm Bowel Dis 2001 Feb, 7(1):68-77.
47. Bullen T.F., Forrest S., Campbell F., Dodson A.R., Hershman M.J., Pritchard D.M., et al. Characterization of epithelial cell shedding from human small intestine. Lab Invest 2006 Oct, 86(10):1052-1063.
48. Russo J.M., Florian P., Shen L., Graham W.V., Tretiakova M.S., Gitter A.H., et al. Distinct temporal-spatial roles for rho kinase and myosin light chain kinase in epithelial purse-string wound closure. Gastroenterology 2005 Apr, 128(4):987-1001.
49. Ciacci C., Lind S.E., Podolsky D.K. Transforming growth factor beta regulation of migration in wounded rat intestinal epithelial monolayers. Gastroenterology 1993 Jul, 105(1):93-101.
50. Dignass A.U., Lynch-Devaney K., Podolsky D.K. Hepatocyte growth factor/scatter factor modulates intestinal epithelial cell proliferation and migration. Biochem Biophys Res Commun 1994 Jul 29, 202(2):701-709.
51. Kato K., Chen M.C., Nguyen M., Lehmann F.S., Podolsky D.K., Soll A.H. Effects of growth factors and trefoil peptides on migration and replication in primary oxyntic cultures. Am J Physiol 1999 May, 276(5 Pt 1):G1105-G1116.
52. Wilson A.J., Gibson P.R. Short-chain fatty acids promote the migration of colonic epithelial cells in vitro. Gastroenterology 1997 Aug, 113(2):487-496.
53. Vandenbroucke K., Hans W., Van Huysse J., Neirynck S., Demetter P., Remaut E., et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004 Aug, 127(2):502-513.
54. Mashimo H., Wu D.C., Podolsky D.K., Fishman M.C. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996 Oct 11, 274(5285):262-265.
55. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004 Jul 23, 118(2):229-241.
56. Pull S.L., Doherty J.M., Mills J.C., Gordon J.I., Stappenbeck T.S. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci U S A 2005 Jan 4, 102(1):99-104.
57. Strauch E.D., Wang J.Y., Bass B.L. Bile salt stimulates intestinal epithelial cell migration through TGFbeta after wounding. J Surg Res 2001 May 1, 97(1):49-53.
58. Karrasch T., Jobin C. NFκB and the intestine: friend or foe?. Inflamm Bowel Dis 2008 Jan, 14(1):114-124.
59. Frey M.R., Edelblum K.L., Mullane M.T., Liang D., Polk D.B. The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF. Gastroenterology 2009 Jan, 136(1):217-226.
60. Owen C.R., Yuan L., Basson M.D. Smad3 knockout mice exhibit impaired intestinal mucosal healing. Lab Invest 2008 Oct, 88(10):1101-1109.
61. Kajino-Sakamoto R., Inagaki M., Lippert E., Akira S., Robine S., Matsumoto K., et al. Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis. J Immunol 2008 Jul 15, 181(2):1143-1152.
62. El-Assal O.N., Besner G.E. HB-EGF enhances restitution after intestinal ischemia/reperfusion via PI3K/Akt and MEK/ERK1/2 activation. Gastroenterology 2005 Aug, 129(2):609-625.
63. Egan L.J., de Lecea A., Lehrman E.D., Myhre G.M., Eckmann L., Kagnoff M.F. Nuclear factor-kappa B activation promotes restitution of wounded intestinal epithelial monolayers. Am J Physiol Cell Physiol 2003 Nov, 285(5):C1028-C1035.
64. Karrasch T., Spaeth T., Allard B., Jobin C. PI3K-dependent GSK3ss(Ser9)-phosphorylation is implicated in the intestinal epithelial cell wound-healing response. PLoS One 2011, 6(10):e26340.
65. Karrasch T., Steinbrecher K.A., Allard B., Baldwin A.S., Jobin C. Wound-induced p38MAPK-dependent histone H3 phosphorylation correlates with increased COX-2 expression in enterocytes. J Cell Physiol 2006 Jun, 207(3):809-815.
66. Bianchi M., De Lucchini S., Marin O., Turner D.L., Hanks S.K., Villa-Moruzzi E. Regulation of FAK Ser-722 phosphorylation and kinase activity by GSK3 and PP1 during cell spreading and migration. Biochem J 2005 Oct 15, 391(Pt 2):359-370.
67. Spehlmann M.E., Eckmann L. Nuclear factor-kappa B in intestinal protection and destruction. Curr Opin Gastroenterol 2009 Mar, 25(2):92-99.
68. Manicassamy S., Reizis B., Ravindran R., Nakaya H., Salazar-Gonzalez R.M., Wang Y.C., et al. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science 2010 Aug 13, 329(5993):849-853.
69. Nava P., Koch S., Laukoetter M.G., Lee W.Y., Kolegraff K., Capaldo C.T., et al. Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signaling pathways. Immunity 2010 Mar 26, 32(3):392-402.
70. ten Hove T., van den Blink B., Pronk I., Drillenburg P., Peppelenbosch M.P., van Deventer S.J. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 2002 Apr, 50(4):507-512.
71. Karrasch T., Kim J.S., Muhlbauer M., Magness S.T., Jobin C. Gnotobiotic IL-10-/-;NF-kappa B(EGFP) mice reveal the critical role of TLR/NF-kappa B signaling in commensal bacteria-induced colitis. J Immunol 2007 May 15, 178(10):6522-6532.
72. Seno H., Miyoshi H., Brown S.L., Geske M.J., Colonna M., Stappenbeck T.S. Efficient colonic mucosal wound repair requires Trem2 signaling. Proc Natl Acad Sci U S A 2009 Jan 6, 106(1):256-261.
73. Tarnawski A., Hollander D., Stachura J., Krause W.J., Eltorai M., Dabros W., et al. Vascular and microvascular changes - key factors in the development of acetic acid-induced gastric ulcers in rats. J Clin Gastroenterol 1990, 12(Suppl 1):S148-S157.
74. Groschwitz K.R., Hogan S.P. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009 Jul, 124(1):3-20. quiz 1-2.
75. Burke J.P., Mulsow J.J., O'Keane C., Docherty N.G., Watson R.W., O'Connell P.R. Fibrogenesis in Crohn's disease. Am J Gastroenterol 2007 Feb, 102(2):439-448.
76. Rieder F., Brenmoehl J., Leeb S., Scholmerich J., Rogler G. Wound healing and fibrosis in intestinal disease. Gut 2007 Jan, 56(1):130-139.
77. Louis E., Collard A., Oger A.F., Degroote E., Aboul Nasr El Yafi F.A., Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001 Dec, 49(6):777-782.
78. Nielsen O.H., Rogler G., Hahnloser D., Thomsen O.O. Diagnosis and management of fistulizing Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2009 Feb, 6(2):92-106.
79. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008 Jan, 214(2):199-210.
80. Vaday G.G., Lider O. Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation. J Leukoc Biol 2000 Feb, 67(2):149-159.
81. Georges P.C., Hui J.J., Gombos Z., McCormick M.E., Wang A.Y., Uemura M., et al. Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol 2007 Dec, 293(6):G1147-G1154.
82. Chiquet M., Gelman L., Lutz R., Maier S. From mechanotransduction to extracellular matrix gene expression in fibroblasts. Biochim Biophys Acta 2009 May, 1793(5):911-920.
83. Rieder F., Fiocchi C. Intestinal fibrosis in IBD - a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol 2009 Apr, 6(4):228-235.
84. Rieder F., Kessler S.P., West G.A., Bhilocha S., de la Motte C., Sadler T.M., et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol 2011 Nov, 179(5):2660-2673. Epub 2011 Sep 21.
85. Foell D., Wittkowski H., Roth J. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat Clin Pract Rheumatol 2007 Jul, 3(7):382-390.
86. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007 Jul 26, 448(7152):427-434.
87. Clutterbuck A.L., Asplin K.E., Harris P., Allaway D., Mobasheri A. Targeting matrix metalloproteinases in inflammatory conditions. Curr Drug Targets 2009 Dec, 10(12):1245-1254.
88. Franke A., McGovern D.P., Barrett J.C., Wang K., Radford-Smith G.L., Ahmad T., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010 Dec, 42(12):1118-1125.
89. Anderson C.A., Boucher G., Lees C.W., Franke A., D'Amato M., Taylor K.D., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011 Mar, 43(3):246-252.
90. Alvarez-Lobos M., Arostegui J.I., Sans M., Tassies D., Plaza S., Delgado S., et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005 Nov, 242(5):693-700.
91. Economou M., Trikalinos T.A., Loizou K.T., Tsianos E.V., Ioannidis J.P. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004 Dec, 99(12):2393-2404.
92. Arijs I., Li K., Toedter G., Quintens R., Van Lommel L., Van Steen K., et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009 Dec, 58(12):1612-1619.
93. Pryde S.E., Duncan S.H., Hold G.L., Stewart C.S., Flint H.J. The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett 2002 Dec 17, 217(2):133-139.
94. Lodes M.J., Cong Y., Elson C.O., Mohamath R., Landers C.J., Targan S.R., et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004 May, 113(9):1296-1306.
95. Segain J.P., Raingeard de la Bletiere D., Bourreille A., Leray V., Gervois N., Rosales C., et al. Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease. Gut 2000 Sep, 47(3):397-403.
96. Luhrs H., Gerke T., Boxberger F., Backhaus K., Melcher R., Scheppach W., et al. Butyrate inhibits interleukin-1-mediated nuclear factor-kappa B activation in human epithelial cells. Dig Dis Sci 2001 Sep, 46(9):1968-1973.
97. Weng M., Walker W.A., Sanderson I.R. Butyrate regulates the expression of pathogen-triggered IL-8 in intestinal epithelia. Pediatr Res 2007 Nov, 62(5):542-546.
98. Finnie I.A., Dwarakanath A.D., Taylor B.A., Rhodes J.M. Colonic mucin synthesis is increased by sodium butyrate. Gut 1995 Jan, 36(1):93-99.
99. Gaudier E., Jarry A., Blottiere H.M., de Coppet P., Buisine M.P., Aubert J.P., et al. Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. Am J Physiol 2004 Dec, 287(6):G1168-G1174.
100. Schwab M., Reynders V., Shastri Y., Loitsch S., Stein J., Schroder O. Role of nuclear hormone receptors in butyrate-mediated up-regulation of the antimicrobial peptide cathelicidin in epithelial colorectal cells. Mol Immunol 2007 Mar, 44(8):2107-2114.
101. Peng L., Li Z.R., Green R.S., Holzman I.R., Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 2009 Sep, 139(9):1619-1625.
102. Lewis K., Lutgendorff F., Phan V., Soderholm J.D., Sherman P.M., McKay D.M. Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate. Inflamm Bowel Dis 2010 Jul, 16(7):1138-1148.
103. Kawamura T., Andoh A., Nishida A., Shioya M., Yagi Y., Nishimura T., et al. Inhibitory effects of short-chain fatty acids on matrix metalloproteinase secretion from human colonic subepithelial myofibroblasts. Dig Dis Sci 2009 Feb, 54(2):238-245.
104. Inatomi O., Andoh A., Kitamura K., Yasui H., Zhang Z., Fujiyama Y. Butyrate blocks interferon-gamma-inducible protein-10 release in human intestinal subepithelial myofibroblasts. J Gastroenterol 2005 May, 40(5):483-489.
105. Pender S.L., Quinn J.J., Sanderson I.R., MacDonald T.T. Butyrate upregulates stromelysin-1 production by intestinal mesenchymal cells. Am J Physiol 2000 Nov, 279(5):G918-G924.
106. Sturm A., Dignass A.U. Epithelial restitution and wound healing in inflammatory bowel disease. World J Gastroenterol 2008 Jan 21, 14(3):348-353.
107. Bantel H., Berg C., Vieth M., Stolte M., Kruis W., Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NFκB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000 Dec, 95(12):3452-3457.
108. Odze R., Antonioli D., Peppercorn M., Goldman H. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol 1993 Sep, 17(9):869-875.
109. Mahida Y.R., Lamming C.E., Gallagher A., Hawthorne A.B., Hawkey C.J. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991 Jan, 32(1):50-54.
110. Doering J., Begue B., Lentze M.J., Rieux-Laucat F., Goulet O., Schmitz J., et al. Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease. Gut 2004 Nov, 53(11):1632-1638.
111. Baumgart D.C., Vierziger K., Sturm A., Wiedenmann B., Dignass A.U. Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism. Scand J Gastroenterol 2005 Aug, 40(8):958-964.
112. Ancha H.R., Kurella R.R., McKimmey C.C., Lightfoot S., Harty R.F. Luminal antioxidants enhance the effects of mesalamine in the treatment of chemically induced colitis in rats. Exp Biol Med (Maywood) 2008 Oct, 233(10):1301-1308.
113. Ardite E., Panes J., Miranda M., Salas A., Elizalde J.I., Sans M., et al. Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease. Br J Pharmacol 1998 Jun, 124(3):431-433.
114. Goke M.N., Schneider M., Beil W., Manns M.P. Differential glucocorticoid effects on repair mechanisms and NFκB activity in the intestinal epithelium. Regul Pept 2002 May 30, 105(3):203-214.
115. Jung S., Fehr S., Harder-d'Heureuse J., Wiedenmann B., Dignass A.U. Corticosteroids impair intestinal epithelial wound repair mechanisms in vitro. Scand J Gastroenterol 2001 Sep, 36(9):963-970.
116. Zushi S., Shinomura Y., Kiyohara T., Minami T., Sugimachi M., Higashimoto Y., et al. Role of prostaglandins in intestinal epithelial restitution stimulated by growth factors. Am J Physiol 1996 May, 270(5 Pt 1):G757-G762.
117. D'Haens G., Geboes K., Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999 Nov, 50(5):667-671.
118. Schroll S., Sarlette A., Ahrens K., Manns M.P., Goke M. Effects of azathioprine and its metabolites on repair mechanisms of the intestinal epithelium in vitro. Regul Pept 2005 Nov, 131(1-3):1-11.
119. Breese E.J., Michie C.A., Nicholls S.W., Murch S.H., Williams C.B., Domizio P., et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994 Jun, 106(6):1455-1466.
120. Suenaert P., Bulteel V., Lemmens L., Noman M., Geypens B., Van Assche G., et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002 Aug, 97(8):2000-2004.
121. Baert F.J., D'Haens G.R., Peeters M., Hiele M.I., Schaible T.F., Shealy D., et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999 Jan, 116(1):22-28.
122. Geboes K., Rutgeerts P., Opdenakker G., Olson A., Patel K., Wagner C.L., et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin 2005 Nov, 21(11):1741-1754.
123. Li Z., Arijs I., De Hertogh G., Vermeire S., Noman M., Bullens D., et al. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis 2010 Aug, 16(8):1299-1310.
124. Prehn J.L., Landers C.J., Targan S.R. A soluble factor produced by lamina propria mononuclear cells is required for TNF-alpha enhancement of IFN-gamma production by T cells. J Immunol 1999 Oct 15, 163(8):4277-4283.
125. Agnholt J., Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001 Aug 21, 15(4):212-222.
126. Arijs I., De Hertogh G., Lemaire K., Quintens R., Van Lommel L., Van Steen K., et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One 2009, 4(11):e7984.
127. Di Sabatino A., Saarialho-Kere U., Buckley M.G., Gordon J.N., Biancheri P., Rovedatti L., et al. Stromelysin-1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn's disease patients treated with infliximab. Eur J Gastroenterol Hepatol 2009 Sep, 21(9):1049-1055.
128. Danese S., Sans M., Scaldaferri F., Sgambato A., Rutella S., Cittadini A., et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006 Feb 15, 176(4):2617-2624.
129. Fratila O.C., Craciun C. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis. J Gastrointestin Liver Dis 2010 Jun, 19(2):147-153.
130. Ng S.C., Hart A.L., Kamm M.A., Stagg A.J., Knight S.C. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009 Feb, 15(2):300-310.
131. Drakes M., Blanchard T., Czinn S. Bacterial probiotic modulation of dendritic cells. Infect Immun 2004 Jun, 72(6):3299-3309.
132. Grabig A., Paclik D., Guzy C., Dankof A., Baumgart D.C., Erckenbrecht J., et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun 2006 Jul, 74(7):4075-4082.
133. Im E., Choi Y.J., Kim C.H., Fiocchi C., Pothoulakis C., Rhee S.H. The angiogenic effect of probiotic Bacillus polyfermenticus on human intestinal microvascular endothelial cells is mediated by IL-8. Am J Physiol 2009 Nov, 297(5):G999-G1008.
134. Fiorucci S., Distrutti E., Mencarelli A., Barbanti M., Palazzini E., Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 2002, 66(4):246-256.
135. Kolios G., Manousou P., Bourikas L., Notas G., Tsagarakis N., Mouzas I., et al. Ciprofloxacin inhibits cytokine-induced nitric oxide production in human colonic epithelium. Eur J Clin Invest 2006 Oct, 36(10):720-729.